Cover of Innovating Clinical Trials

Innovating Clinical Trials

Innovating Clinical Trials

By: Liam Eves and Ted Trafford
Listen for free

Season's Savings | 0.99 €/month for 3 months

5.99 €/month thereafter - terms apply. Cancel monthly.
Summary

Welcome to Innovating Clinical Trials, the podcast designed for clinical research professionals eager to deepen their understanding of clinical trials through concise, insightful segments. Join your hosts, Liam Eves and Ted Trafford, as they uncover the core issues in clinical research, reflect on the industry, and challenge conventional wisdom.

Ted Trafford - https://probitymedical.com/
With 30 years of experience in clinical research, Ted serves as the Director of Business Development, driving business growth and leading Feasibility and Site Relationship teams at Probity Medical Research, a clinical trial site administrative support company with a consortium of 75+ sites across four countries. As a writer and speaker, Ted contributes to thought leadership and strategic initiatives in the clinical trials industry, leveraging his extensive experience and creative approach to drive meaningful discussion and progress for Sponsors, CROs, Sites and Technology Vendors.

Liam Eves - https://www.theendpointpodcast.com/
Liam's held executive roles in SMOs and CROs, and led all major functions of trial delivery. His journey into the field began unexpectedly after an injury ended his career as a professional footballer. Over the years Liam has optimized trial delivery methods / systems for effective enrollment and trial delivery. Currently, he focuses on building and advising companies in the clinical trial space.



Opinions expressed are those of the participants and not their employers.

© 2026 Innovating Clinical Trials
Science
Episodes
  • ICT Ep 2.49: Joseph Kim on Why Your Enrollment Forecast Is Sixth-Grade Math (Part 3/3)
    17 Nov 2026

    In the final part of this three-part conversation, Liam and Ted turn to enrollment forecasting with Joseph Kim, Chief Strategy Officer at ProofPilot, who says it has been done in "such a dangerously naive way."

    His first target is what he calls algebra one: take the number of patients and the number of sites, solve for the months, and draw a straight line. Anyone who has run one study knows enrollment doesn't work like that. The curve is S-shaped, because countries and sites start on a rolling basis and screen failure ratios differ by site and by country. He reads the straight-line answer as the fastest a study could go, and no more.

    Benchmarks help, but they age. Joseph tells the story of the second-generation Gardasil studies at Merck. Australia had enrolled very well for the first vaccine, so the plan assumed it would again. It didn't, because by then girls and women there were already well vaccinated and could get the first version for free. Liam has seen the same in erectile dysfunction, where a study competes with today's standard of care and an old benchmark doesn't show it.

    Joseph then lays out how he would build a forecast: a quick curve a year out, refined with an analysis of how many patients the inclusion and exclusion criteria remove, then your own operational data, and finally each named site's own plan once sites are selected. When the clock starts, that plan is already out of date, so you track the inputs: site activation, screening and screen failure rates. Liam's rule is to be roughly right, not precisely wrong.

    The episode ends on what happens when enrollment falls behind and management says "get to 2.7 patients per site per month." Joseph compares it to sleep. If you wanted eight hours and got four, telling yourself to sleep more does nothing. You look at the coffee and the two hours of screens before bed. Ted adds the site view: when things go wrong and the sponsor goes silent for weeks, sites turn their attention elsewhere.

    Find Joseph on LinkedIn and at proofpilot.com.


    Show more Show less
    18 min
  • ICT Ep 2.48: Joseph Kim on the Mystery Drug Patients Never Get Told About (Part 2/3)
    17 Nov 2026

    In Part 2 of this three-part conversation, Liam and Ted ask Joseph Kim, Chief Strategy Officer at ProofPilot, a question he expects to get him into trouble: if patients are at the center of everything we do, why don't we tell them how the study turned out?

    The prompt is a draft NIH policy on sharing summary results with participants in plain language. Joseph's view is that you can't call yourself patient-centric and skip this. The lay summary is the easy part, because everyone gets the same one. Send it to participants directly, or give sites a line item to do it, since by then the contracts are usually closed. Posting it on a website and telling nobody doesn't count.

    He explains patient-centric by swapping the word. A child-centric room has low stools, juice boxes and padding in the right places. The science stays as rigorous as it needs to be, and the experience around it gets built for the person in it. Ted adds his own picture: a school that never sends a report card home.

    Then Joseph goes a level deeper and says people should get their own data back. He names five things that are safe to return: which drug they were on, their primary endpoint, vitals, adverse events and safety labs. His example is a psoriasis patient whose migraines got worse on the study drug and who dropped out. A few years later a new doctor prescribes the same drug, now on the market, and neither of them knows. He also argues that returning results would do more for research awareness than any campaign.

    Why doesn't it happen? Joseph grants the real fear of pre-approval promotion, then says the bigger reason is that we aren't thinking about the participant. Frameworks already exist from TransCelerate and the MRCT Center, and the data already sits in rows and columns. Liam closes on choice: if a participant doesn't want their results, fine, but offer them. Joseph's last word is that the technology exists and what's missing is the political will.


    Show more Show less
    21 min
  • ICT Ep 2.47: Joseph Kim Asks: Is Your Screen Failure Ratio Payment Policy Oriented Around Trust or Suspicion? (Part 1/3)
    17 Nov 2026

    In Part 1 of this three-part conversation, Liam and Ted sit down with Joseph Kim, Chief Strategy Officer at ProofPilot, who brings more than 27 years of pharmaceutical research experience. He joined ProofPilot from Lilly, where he was Senior Advisor in the Digital Health Office and Clinical Innovation, and has worked for sponsors including Merck and Takeda (Shire), as well as CROs and technology vendors. CenterWatch named him one of 20 innovators changing the face of the clinical trials industry, and he was on the MedicineMaker Power List in 2015.

    Joseph's parents were street vendors and he had no network, so his molecular biology degree from Lehigh led first to social work and then to teaching high school science. A friend got him a three-month contract at Merck reviewing paper case report forms, and by 1999 he was a study manager writing consent forms, picking sites and paying investigators with an electric typewriter and a paper check. He calls his approach "lazy smart": he built a spreadsheet of canned wording so he never had to write a data query from scratch, and once sent sites queries about visits that hadn't happened yet.

    Then the topic: screen failure ratio payments, where a sponsor pays for only a set number of screen failures per randomized patient. Joseph's guess is that the term goes back to a bad actor screening patients they knew wouldn't qualify. His argument is that this is easy to catch, because a site more than one standard deviation from the average screening rate can be flagged and looked at, and that the small cost of some bad behavior is tiny next to the value of good sites that keep screening. His question for sponsors: is your screen failure ratio payment policy oriented around trust or suspicion?

    Ted brings the site view: toenail fungus studies where ten patients had to be screened to find one with a positive lab result, against a budget that paid for five screen failures. He also cites the SCRS 2024 site landscape survey, in which 42% of sites said screen failure terms never or only sometimes cover the actual number. Liam calls it the iceberg problem: most people think the study starts at randomization, and the work to get a patient that far goes unpaid.

    Joseph's advice for a sponsor's next study is to strike the line from the contract, or replace it with an expectation and a closer look if a site runs 50% over. The episode closes with a rapid-fire keep it or kill it on paid pre-screening, holdbacks and monthly site payments.


    Show more Show less
    22 min
adbl_web_anon_alc_button_suppression_t1
No reviews yet